- Home
- NRC vs ALT Comparison
NRC vs ALT Comparison
Compare NRC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRC | ALT |
|---|---|---|
| Founded | 1981 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.1M | 421.5M |
| IPO Year | 1997 | 2005 |
Fundamental Metrics
Financial Performance| Metric | NRC | ALT |
|---|---|---|
| Price | $20.04 | $2.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 166.3K | ★ 3.3M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | ★ 4707.69 | 25.37 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $119,686,000.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $139.21 | ★ N/A |
| Revenue Growth | 1.81 | ★ 105.00 |
| 52 Week Low | $11.01 | $2.56 |
| 52 Week High | $22.79 | $7.73 |
Technical Indicators
Market Signals| Indicator | NRC | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 56.38 | 56.96 |
| Support Level | $18.03 | $2.87 |
| Resistance Level | $21.33 | $3.20 |
| Average True Range (ATR) | 1.17 | 0.13 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 63.00 | 83.15 |
Price Performance
Historical ComparisonAbout NRC National Research Corporation (Delaware)
NRC Health operates as a humanized healthcare and support organization. Its platform includes Listen, Understand, and Improve. The group provides solutions for Patient, Consumer, Employee, and Market experiences. The group's commitment to Human Understanding helps healthcare systems get to know the patients, families, consumers, employees, and communities it on a human level.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.